VIR
Live chart
What they do
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.
For information only · Important disclosures
Grades vs sector
Momentum94th percentile in sectorA
Percentile within its GICS sector across the S&P 1500.
Growth100th percentile in sectorA+
Percentile within its GICS sector across the S&P 1500.
ValueNot enough data yet–
Percentile within its GICS sector across the S&P 1500.
Profitability5th percentile in sectorF
Percentile within its GICS sector across the S&P 1500.
RevisionsNot enough data yet–
30-day change in analysts' current-year EPS estimate; graded across covered stocks.
Our models
Not held by any of our 5 live models right now.
News
More newsKey stats
Valuation and fundamentals
Valuation & fundamentals
Discounted cash flow
Edit assumptions · recalculates instantly
Free cash flow = operating cash flow − capital spending, trailing 12 months (TTM to 2026-06-30). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 1.59 × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.
Multiples vs Health Care
pricier
cheaper
pricier
Forward EPS $-2.49 vs trailing $-1.76. Forward P/E uses analysts' next-12-month estimate.
Quality & financial health
Piotroski F-score 3/9 · last two fiscal years
Altman Z-score 3.1 (safe zone; above 3.0 = safe, below 1.8 = distress). Not meaningful for banks and insurers.
Analysts
Annual history
| FY | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | $68.6M | $-438.0M | $-396.6M |
| 2024 | $74.2M | $-522.0M | $-453.7M |
| 2023 | $86.2M | $-615.1M | $-800.4M |
| 2022 | $1.6B | $515.8M | $1.6B |
| 2021 | $1.1B | $528.6M | $-69.4M |
| 2020 | $76.4M | $-298.7M | $-197.5M |
From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR -65.1%.
Earnings
| Report | EPS est | Actual | Surprise |
|---|---|---|---|
| 2026-08-05 | 0.90 | 0.47 | -47.5% |
| 2026-05-06 | 0.48 | -0.85 | -276.6% |
| 2026-02-23 | -0.45 | -0.31 | +31.6% |
| 2025-11-05 | -0.86 | -1.17 | -36.0% |
| 2025-08-06 | -0.72 | -0.80 | -11.4% |
| 2025-05-07 | -0.84 | -0.88 | -4.3% |
| 2025-02-26 | -0.87 | -0.76 | +12.7% |
| 2024-10-31 | -1.08 | -1.56 | -44.0% |
Quarterly revenue
| Quarter | Revenue | YoY |
|---|---|---|
| 2026-06-30 | $238.9M | +23075.1% |
| 2026-03-31 | $-41.0K | – |
| 2025-12-31 | $63.8M | – |
| 2025-09-30 | $-65.0K | – |
| 2025-06-30 | $1.0M | – |
Analyst actions
PT $22
PT $27
PT $21
PT $20
PT $30
PT $24
Insider trades
–
Stats refreshed 2026-10-21 18:22:38 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now
Independent research · Not investment advice · Important disclosures · Contact desk@coteau.app
Coteau Systematic Strategies publishes stock research and model portfolios. Results are hypothetical unless marked Live. Data: Yahoo Finance (15-min delayed), SEC EDGAR and the House Clerk.
Beta 0.9 · Oct 21, 2026